Wei-Sheng Huang

Wei-Sheng Huang, Ph.D. joined Kojin as Senior Vice President, Drug Discovery in February 2024.

Dr. Huang brings over 20 years of R&D experience to Kojin. Most recently, he was Senior Vice President of Chemistry at Theseus Pharmaceuticals, where he held a leadership role in advancing the drug pipeline, including the discovery of development candidate compounds THE-630 and THE-349. Prior to Theseus, he was Director of Discovery Chemistry at ARIAD Pharmaceuticals, where he served for 14 years and led the medicinal chemistry team that was the engine behind the discovery of Iclusig®, approved for patients with treatment-resistant Ph+ leukemias; Alunbrig®, approved for ALK+ non-small cell lung cancer (NSCLC); and Exkivity®, approved for EGFR Exon 20 insertion+ NSCLC. Dr. Huang started his industrial career in 2001 as a senior scientist at UCB Pharma, where he focused on discovering sigma-receptor agonists and opioid-receptor-like-1 antagonists.

Dr. Huang conducted postdoctoral research at the University of Virginia and Massachusetts Institute of Technology. He received his Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Science and his B.S. from Huazhong University of Science and Technology.

Dr. Huang has co-authored over 50 publications in peer-reviewed journals and is co-inventor on over 30 granted patents or patent applications.